Uncategorized
AGTC files investigational NDA for X-linked retinitis pigmentosa gene therapy
Applied Genetic Technologies Corporation has filed an investigational new drug application with the FDA to begin a phase 1/2 clinical trial of its gene therapy candidate for X-linked retinitis pigmentosa, according to a company press release.X-linked retinitis pigmentosa, caused by mutations in the RPGR gene, is an inherited condition that causes progressive vision loss. In preclinical data, AGTC’s investigational gene therapy has slowed the loss of visual function in canines with X-linked retinitis pigmentosa, according to the release.